{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T16:06:17Z","timestamp":1781625977809,"version":"3.54.5"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T00:00:00Z","timestamp":1776816000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T00:00:00Z","timestamp":1776816000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Pharmacokinet"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1007\/s40262-026-01635-3","type":"journal-article","created":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T15:43:49Z","timestamp":1776872629000},"page":"863-882","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Clinical Validation of Venetoclax Volumetric Microsampling in Patients with Leukemia with Assessment of Whole-Blood-to-Plasma Conversion Strategies and Self-Microsampling Feasibility"],"prefix":"10.1007","volume":"65","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2107-4693","authenticated-orcid":false,"given":"A. D.","family":"Levens","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Rijstenbil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Metscher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"von dem Borne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Albersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. J.","family":"Swen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3219-253X","authenticated-orcid":false,"given":"D. J. A. R.","family":"Moes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,22]]},"reference":[{"key":"1635_CR1","doi-asserted-by":"publisher","DOI":"10.3390\/jpm11060463","author":"M Lasica","year":"2021","unstructured":"Lasica M, Anderson MA. Review of venetoclax in CLL, AML and multiple myeloma. J Pers Med. 2021. https:\/\/doi.org\/10.3390\/jpm11060463.","journal-title":"J Pers Med"},{"key":"1635_CR2","unstructured":"Agency EM: Venclyxto (venetoclax) summary of product characteristics. 2023. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/venclyxto. Accessed 13 Mar 2025."},{"issue":"4","key":"1635_CR3","doi-asserted-by":"publisher","first-page":"400","DOI":"10.6004\/jadpro.2022.13.4.4","volume":"13","author":"M Waggoner","year":"2022","unstructured":"Waggoner M, Katsetos J, Thomas E, Galinsky I, Fox H. Practical management of the venetoclax-treated patient in chronic lymphocytic leukemia and acute myeloid leukemia. J Adv Pract Oncol. 2022;13(4):400\u201315. https:\/\/doi.org\/10.6004\/jadpro.2022.13.4.4.","journal-title":"J Adv Pract Oncol"},{"issue":"8","key":"1635_CR4","doi-asserted-by":"publisher","first-page":"3179","DOI":"10.1007\/s00277-024-05676-1","volume":"103","author":"MF Kt","year":"2024","unstructured":"Kt MF, Semwal M, Yoosuf BT, Lad D, Bansal D. Venetoclax adverse event monitoring: a safety meta-analysis of randomized controlled trials and a retrospective evaluation of the FAERS. Ann Hematol. 2024;103(8):3179\u201391. https:\/\/doi.org\/10.1007\/s00277-024-05676-1.","journal-title":"Ann Hematol"},{"key":"1635_CR5","unstructured":"Research CfDEa. Clinical pharmacology and biopharmaceutics review: NDA 208573 venetoclax. Silver Spring: U.S. Food and Drug Administration; 2016."},{"issue":"1","key":"1635_CR6","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1097\/ftd.0000000000001151","volume":"46","author":"M Philippe","year":"2024","unstructured":"Philippe M, Guitton J, Goutelle S, Thoma Y, Favier B, Chtiba N, et al. Pharmacokinetic consideration of venetoclax in acute myeloid leukemia patients: a potential candidate for TDM? A short communication. Ther Drug Monit. 2024;46(1):127\u201331. https:\/\/doi.org\/10.1097\/ftd.0000000000001151.","journal-title":"Ther Drug Monit"},{"issue":"12","key":"1635_CR7","doi-asserted-by":"publisher","DOI":"10.1007\/s12032-022-01865-y","volume":"39","author":"M Kobayashi","year":"2022","unstructured":"Kobayashi M, Yasu T, Suzaki K, Kosugi N. Utility of therapeutic drug monitoring of venetoclax in acute myeloid leukemia. Med Oncol. 2022;39(12):259. https:\/\/doi.org\/10.1007\/s12032-022-01865-y.","journal-title":"Med Oncol"},{"issue":"5","key":"1635_CR8","doi-asserted-by":"publisher","DOI":"10.1111\/cts.13807","volume":"17","author":"AH Salem","year":"2024","unstructured":"Salem AH, Menon RM. Clinical pharmacokinetics and pharmacodynamics of venetoclax, a selective B-cell lymphoma-2 inhibitor. Clin Transl Sci. 2024;17(5):e13807. https:\/\/doi.org\/10.1111\/cts.13807.","journal-title":"Clin Transl Sci"},{"key":"1635_CR9","doi-asserted-by":"publisher","first-page":"1771","DOI":"10.2147\/dddt.S458927","volume":"18","author":"Y Zhao","year":"2024","unstructured":"Zhao Y, Guo N, Zhu Y, Shang J, Chen J, Luo X, et al. Population pharmacokinetic models of venetoclax in hematologic malignancies: a systematic review. Drug Des Dev Ther. 2024;18:1771\u201384. https:\/\/doi.org\/10.2147\/dddt.S458927.","journal-title":"Drug Des Dev Ther"},{"issue":"2","key":"1635_CR10","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1016\/j.clinthera.2017.01.003","volume":"39","author":"SK Agarwal","year":"2017","unstructured":"Agarwal SK, DiNardo CD, Potluri J, Dunbar M, Kantarjian HM, Humerickhouse RA, et al. Management of venetoclax-posaconazole interaction in acute myeloid leukemia patients: evaluation of dose adjustments. Clin Ther. 2017;39(2):359\u201367. https:\/\/doi.org\/10.1016\/j.clinthera.2017.01.003.","journal-title":"Clin Ther"},{"key":"1635_CR11","unstructured":"Administration USFaD: VENCLEXTA (venetoclax) prescribing information. 2019. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/208573s013lbl.pdf. Accessed 17 Mar 2025."},{"key":"1635_CR12","unstructured":"Nederland SH-OvV: a trial to assess cobicistat boosted venetoclax in combination with azacitidine in adult patients with newly diagnosed AML (HO171). 2024. https:\/\/clinicaltrials.gov\/study\/NCT06014489?term=HO171%20AML&rank=1. Accessed."},{"key":"1635_CR13","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics15041149","author":"N Westra","year":"2023","unstructured":"Westra N, Touw D, Lub-de Hooge M, Kosterink J, Oude Munnink T. Pharmacokinetic boosting of kinase inhibitors. Pharmaceutics. 2023. https:\/\/doi.org\/10.3390\/pharmaceutics15041149.","journal-title":"Pharmaceutics"},{"issue":"4","key":"1635_CR14","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1007\/s00228-020-03014-8","volume":"77","author":"A Mueller-Schoell","year":"2021","unstructured":"Mueller-Schoell A, Groenland SL, Scherf-Clavel O, van Dyk M, Huisinga W, Michelet R, et al. Therapeutic drug monitoring of oral targeted antineoplastic drugs. Eur J Clin Pharmacol. 2021;77(4):441\u201364. https:\/\/doi.org\/10.1007\/s00228-020-03014-8.","journal-title":"Eur J Clin Pharmacol"},{"issue":"11","key":"1635_CR15","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1007\/s40262-014-0177-7","volume":"53","author":"AJ Wilhelm","year":"2014","unstructured":"Wilhelm AJ, den Burger JCG, Swart EL. Therapeutic drug monitoring by dried blood spot: progress to date and future directions. Clin Pharmacokinet. 2014;53(11):961\u201373. https:\/\/doi.org\/10.1007\/s40262-014-0177-7.","journal-title":"Clin Pharmacokinet"},{"key":"1635_CR16","doi-asserted-by":"publisher","first-page":"S13","DOI":"10.1016\/j.critrevonc.2003.04.001","volume":"48","author":"G Avvisati","year":"2003","unstructured":"Avvisati G, Tirindelli MC, Annibali O. Thrombocytopenia and hemorrhagic risk in cancer patients. Crit Rev Oncol Hematol. 2003;48:S13\u20136. https:\/\/doi.org\/10.1016\/j.critrevonc.2003.04.001.","journal-title":"Crit Rev Oncol Hematol"},{"issue":"5","key":"1635_CR17","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1007\/s13318-023-00846-4","volume":"48","author":"NNB Zailani","year":"2023","unstructured":"Zailani NNB, Ho PC. Dried blood spots-a platform for therapeutic drug monitoring (TDM) and drug\/disease response monitoring (DRM). Eur J Drug Metab Pharmacokinet. 2023;48(5):467\u201394. https:\/\/doi.org\/10.1007\/s13318-023-00846-4.","journal-title":"Eur J Drug Metab Pharmacokinet"},{"issue":"5","key":"1635_CR18","doi-asserted-by":"publisher","DOI":"10.1002\/bmc.70056","volume":"39","author":"M Meertens","year":"2025","unstructured":"Meertens M, Rosing H, Steeghs N, Beijnen JH, Huitema ADR. Advancing therapeutic drug monitoring for oral targeted anticancer drugs: from hospital-based towards home-sampling. Biomed Chromatogr. 2025;39(5):e70056. https:\/\/doi.org\/10.1002\/bmc.70056.","journal-title":"Biomed Chromatogr"},{"issue":"4","key":"1635_CR19","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1097\/ftd.0000000000000643","volume":"41","author":"S Capiau","year":"2019","unstructured":"Capiau S, Veenhof H, Koster RA, Bergqvist Y, Boettcher M, Halmingh O, et al. Official International Association for Therapeutic Drug Monitoring and Clinical Toxicology guideline: development and validation of dried blood spot-based methods for therapeutic drug monitoring. Ther Drug Monit. 2019;41(4):409\u201330. https:\/\/doi.org\/10.1097\/ftd.0000000000000643.","journal-title":"Ther Drug Monit"},{"issue":"4","key":"1635_CR20","doi-asserted-by":"publisher","DOI":"10.1208\/s12248-024-00947-1","volume":"26","author":"L Boffel","year":"2024","unstructured":"Boffel L, Van Mensel A, Pauwels J, Den Hond E, Bessems J, Van Uytfanghe K, et al. Self-sampling by adolescents at home: assessment of the feasibility to successfully collect blood microsamples by inexperienced individuals. AAPS J. 2024;26(4):75. https:\/\/doi.org\/10.1208\/s12248-024-00947-1.","journal-title":"AAPS J"},{"key":"1635_CR21","unstructured":"LUMC: Medicijnmeting thuis via een vingerprik afname: dried blood spot (DBS). 2025. https:\/\/www.lumc.nl\/afdelingen\/klinisch-chemisch-laboratorium\/overige-folders\/medicijnmeting-thuis-via-een-vingerprik-afname-dried-blood-spot-dbs\/. Accessed 17 July 2025."},{"key":"1635_CR22","unstructured":"EMA. 2025. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/venclyxto-epar-product-information_en.pdf. Accessed 17 July 2025."},{"issue":"4","key":"1635_CR23","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1002\/jcph.821","volume":"57","author":"AH Salem","year":"2017","unstructured":"Salem AH, Agarwal SK, Dunbar M, Enschede SL, Humerickhouse RA, Wong SL. Pharmacokinetics of venetoclax, a novel BCL-2 inhibitor, in patients with relapsed or refractory chronic lymphocytic leukemia or non-Hodgkin lymphoma. J Clin Pharmacol. 2017;57(4):484\u201392. https:\/\/doi.org\/10.1002\/jcph.821.","journal-title":"J Clin Pharmacol"},{"key":"1635_CR24","unstructured":"ICH: ICH guideline M10 on bioanalytical method validation and study sample analysis. 2023. https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/ich-guideline-m10-bioanalytical-method-validation-step-5_en.pdf. Accessed 17 July 2025."},{"issue":"5","key":"1635_CR25","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1007\/s11095-021-03036-6","volume":"38","author":"V Iacuzzi","year":"2021","unstructured":"Iacuzzi V, Posocco B, Zanchetta M, Gagno S, Poetto AS, Guardascione M, et al. Dried blood spot technique applied in therapeutic drug monitoring of anticancer drugs: a review on conversion methods to correlate plasma and dried blood spot concentrations. Pharm Res. 2021;38(5):759\u201378. https:\/\/doi.org\/10.1007\/s11095-021-03036-6.","journal-title":"Pharm Res"},{"issue":"10","key":"1635_CR26","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1111\/jphp.12757","volume":"69","author":"C Boons","year":"2017","unstructured":"Boons C, Chahbouni A, Schimmel AM, Wilhelm AJ, den Hartog YM, Janssen J, et al. Dried blood spot sampling of nilotinib in patients with chronic myeloid leukaemia: a comparison with venous blood sampling. J Pharm Pharmacol. 2017;69(10):1265\u201374. https:\/\/doi.org\/10.1111\/jphp.12757.","journal-title":"J Pharm Pharmacol"},{"issue":"1","key":"1635_CR27","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1007\/s10549-014-2999-2","volume":"146","author":"NG Jager","year":"2014","unstructured":"Jager NG, Rosing H, Schellens JH, Beijnen JH, Linn SC. Use of dried blood spots for the determination of serum concentrations of tamoxifen and endoxifen. Breast Cancer Res Treat. 2014;146(1):137\u201344. https:\/\/doi.org\/10.1007\/s10549-014-2999-2.","journal-title":"Breast Cancer Res Treat"},{"issue":"10","key":"1635_CR28","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.1002\/jcph.728","volume":"56","author":"CM Nijenhuis","year":"2016","unstructured":"Nijenhuis CM, Huitema AD, Marchetti S, Blank C, Haanen JB, van Thienen JV, et al. The use of dried blood spots for pharmacokinetic monitoring of vemurafenib treatment in melanoma patients. J Clin Pharmacol. 2016;56(10):1307\u201312. https:\/\/doi.org\/10.1002\/jcph.728.","journal-title":"J Clin Pharmacol"},{"issue":"16","key":"1635_CR29","doi-asserted-by":"publisher","first-page":"2105","DOI":"10.4155\/bio.15.101","volume":"7","author":"MV Antunes","year":"2015","unstructured":"Antunes MV, Raymundo S, Wagner SC, Mattevi VS, Vieira N, Leite R, et al. DBS sampling in imatinib therapeutic drug monitoring: from method development to clinical application. Bioanalysis. 2015;7(16):2105\u201317. https:\/\/doi.org\/10.4155\/bio.15.101.","journal-title":"Bioanalysis"},{"key":"1635_CR30","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.jpba.2017.11.079","volume":"150","author":"RZ Hahn","year":"2018","unstructured":"Hahn RZ, Arnhold PC, Andriguetti NB, Schneider A, Kl\u00fcck HM, Dos Reis SL, et al. Determination of irinotecan and its metabolite SN-38 in dried blood spots using high-performance liquid-chromatography with fluorescence detection. J Pharm Biomed Anal. 2018;150:51\u20138. https:\/\/doi.org\/10.1016\/j.jpba.2017.11.079.","journal-title":"J Pharm Biomed Anal"},{"key":"1635_CR31","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.clinbiochem.2018.02.020","volume":"54","author":"NB Andriguetti","year":"2018","unstructured":"Andriguetti NB, Hahn RZ, Lizot LF, Raymundo S, Costa JL, da Cunha KF, et al. Analytical and clinical validation of a dried blood spot assay for the determination of paclitaxel using high-performance liquid chromatography-tandem mass spectrometry. Clin Biochem. 2018;54:123\u201330. https:\/\/doi.org\/10.1016\/j.clinbiochem.2018.02.020.","journal-title":"Clin Biochem"},{"key":"1635_CR32","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.jpba.2018.05.011","volume":"157","author":"S Raymundo","year":"2018","unstructured":"Raymundo S, Muller VV, Andriguetti NB, Tegner M, Artmann AC, Kluck HM, et al. Determination of docetaxel in dried blood spots by LC-MS\/MS: method development, validation and clinical application. J Pharm Biomed Anal. 2018;157:84\u201391. https:\/\/doi.org\/10.1016\/j.jpba.2018.05.011.","journal-title":"J Pharm Biomed Anal"},{"key":"1635_CR33","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/j.jchromb.2012.07.011","volume":"903","author":"E Kralj","year":"2012","unstructured":"Kralj E, Trontelj J, Paji\u010d T, Kristl A. Simultaneous measurement of imatinib, nilotinib and dasatinib in dried blood spot by ultra high performance liquid chromatography tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 2012;903:150\u20136. https:\/\/doi.org\/10.1016\/j.jchromb.2012.07.011.","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"key":"1635_CR34","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.cca.2015.10.026","volume":"452","author":"R Re\u017eonja Kukec","year":"2016","unstructured":"Re\u017eonja Kukec R, Grabnar I, Mrhar A, \u010cebron Lipovec N, \u010cufer T, Vovk T. A simple dried blood spot method for clinical pharmacological analyses of etoposide in cancer patients using liquid chromatography and fluorescence detection. Clin Chim Acta. 2016;452:99\u2013105. https:\/\/doi.org\/10.1016\/j.cca.2015.10.026.","journal-title":"Clin Chim Acta"},{"issue":"11","key":"1635_CR35","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0225225","volume":"14","author":"V Iacuzzi","year":"2019","unstructured":"Iacuzzi V, Posocco B, Zanchetta M, Montico M, Marangon E, Poetto AS, et al. Development and validation of LC-MS\/MS method for imatinib and norimatinib monitoring by finger-prick DBS in gastrointestinal stromal tumor patients. PLoS ONE. 2019;14(11):e0225225. https:\/\/doi.org\/10.1371\/journal.pone.0225225.","journal-title":"PLoS ONE"},{"issue":"12","key":"1635_CR36","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1002\/jcph.558","volume":"55","author":"D de Wit","year":"2015","unstructured":"de Wit D, den Hartigh J, Gelderblom H, Qian Y, den Hollander M, Verheul H, et al. Dried blood spot analysis for therapeutic drug monitoring of pazopanib. J Clin Pharmacol. 2015;55(12):1344\u201350. https:\/\/doi.org\/10.1002\/jcph.558.","journal-title":"J Clin Pharmacol"},{"issue":"5","key":"1635_CR37","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1111\/jcpt.13124","volume":"45","author":"J Lee","year":"2020","unstructured":"Lee J, Jung SY, Choi MY, Park JS, Park SK, Lim SA, et al. Development of a dried blood spot sampling method towards therapeutic monitoring of radotinib in the treatment of chronic myeloid leukaemia. J Clin Pharm Ther. 2020;45(5):1006\u201313. https:\/\/doi.org\/10.1111\/jcpt.13124.","journal-title":"J Clin Pharm Ther"},{"key":"1635_CR38","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1016\/j.talanta.2014.10.040","volume":"132","author":"MV Antunes","year":"2015","unstructured":"Antunes MV, Raymundo S, de Oliveira V, Staudt DE, G\u00f6ssling G, Peteffi GP, et al. Ultra-high performance liquid chromatography tandem mass spectrometric method for the determination of tamoxifen, N-desmethyltamoxifen, 4-hydroxytamoxifen and endoxifen in dried blood spots--development, validation and clinical application during breast cancer adjuvant therapy. Talanta. 2015;132:775\u201384. https:\/\/doi.org\/10.1016\/j.talanta.2014.10.040.","journal-title":"Talanta"},{"issue":"2","key":"1635_CR39","doi-asserted-by":"publisher","first-page":"123","DOI":"10.4155\/bio.15.235","volume":"8","author":"RB Verheijen","year":"2016","unstructured":"Verheijen RB, Bins S, Thijssen B, Rosing H, Nan L, Schellens JH, et al. Development and clinical validation of an LC-MS\/MS method for the quantification of pazopanib in DBS. Bioanalysis. 2016;8(2):123\u201334. https:\/\/doi.org\/10.4155\/bio.15.235.","journal-title":"Bioanalysis"},{"key":"1635_CR40","doi-asserted-by":"publisher","unstructured":"Boffel L, De Baets H, Heughebaert L, Rispens T, \u00c5sberg A, Shipkova M, et al. To convert or not to convert? Official International Association of Therapeutic Drug Monitoring and Clinical Toxicology guideline: considerations and recommendations for converting capillary blood microsampling concentrations to plasma concentrations. Ther Drug Monit. https:\/\/doi.org\/10.1097\/FTD.0000000000001393.","DOI":"10.1097\/FTD.0000000000001393"},{"key":"1635_CR41","doi-asserted-by":"publisher","unstructured":"Passing H, Bablok. A new biometrical procedure for testing the equality of measurements from two different analytical methods. Application of linear regression procedures for method comparison studies in clinical chemistry, Part I. J Clin Chem Clin Biochem. 1983;21(11):709\u201320. https:\/\/doi.org\/10.1515\/cclm.1983.21.11.709.","DOI":"10.1515\/cclm.1983.21.11.709"},{"issue":"8476","key":"1635_CR42","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/S0140-6736(86)90837-8","volume":"1","author":"JM Bland","year":"1986","unstructured":"Bland JM, Altman DG. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet. 1986;1(8476):307\u201310.","journal-title":"Lancet"},{"key":"1635_CR43","unstructured":"(Australia) TGA. AusPAR Attachment 2: Extract from the Clinical Evaluation Report for Venetoclax (Venclexta). Commonwealth of Australia; 2016."},{"issue":"2","key":"1635_CR44","first-page":"29","volume":"8","author":"J Brooke","year":"2013","unstructured":"Brooke J. SUS: a retrospective. J Usability Stud. 2013;8(2):29\u201340.","journal-title":"J Usability Stud"},{"key":"1635_CR45","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1016\/j.jpba.2018.10.010","volume":"163","author":"S Velghe","year":"2019","unstructured":"Velghe S, Delahaye L, Stove CP. Is the hematocrit still an issue in quantitative dried blood spot analysis? J Pharm Biomed Anal. 2019;163:188\u201396. https:\/\/doi.org\/10.1016\/j.jpba.2018.10.010.","journal-title":"J Pharm Biomed Anal"},{"key":"1635_CR46","doi-asserted-by":"publisher","DOI":"10.1097\/FTD.0000000000000887","author":"M Luginb\u00fchl","year":"2021","unstructured":"Luginb\u00fchl M, Gaugler S. Addressing new possibilities and new challenges: automated nondestructive hematocrit normalization for dried blood spots. Ther Drug Monit. 2021. https:\/\/doi.org\/10.1097\/FTD.0000000000000887.","journal-title":"Ther Drug Monit"},{"key":"1635_CR47","doi-asserted-by":"publisher","DOI":"10.1016\/j.microc.2024.111330","volume":"205","author":"L Heughebaert","year":"2024","unstructured":"Heughebaert L, Boffel L, L\u00fchr C, Lambrecht S, Stove CP. Near-infrared-based hematocrit determination of dried blood samples collected by volumetric absorptive microsampling: an in-depth evaluation. Microchem J. 2024;205:111330. https:\/\/doi.org\/10.1016\/j.microc.2024.111330.","journal-title":"Microchem J"},{"issue":"21","key":"1635_CR48","doi-asserted-by":"publisher","DOI":"10.3390\/app14219860","volume":"14","author":"C Daousani","year":"2024","unstructured":"Daousani C, Kosti\u0107 N, Malenovi\u0107 A, Rmandi\u0107 M, Dotsikas Y. On the use of image analysis for hematocrit evaluation in dried blood spots. Appl Sci Basel. 2024;14(21):9860.","journal-title":"Appl Sci Basel"},{"key":"1635_CR49","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpba.2023.115311","volume":"228","author":"S Zimmermann","year":"2023","unstructured":"Zimmermann S, Aghai-Trommeschlaeger F, Kraus S, Grigoleit GU, Gesierich A, Schilling B, et al. Clinical validation and assessment of feasibility of volumetric absorptive microsampling (VAMS) for monitoring of nilotinib, cabozantinib, dabrafenib, trametinib, and ruxolitinib. J Pharm Biomed Anal. 2023;228:115311. https:\/\/doi.org\/10.1016\/j.jpba.2023.115311.","journal-title":"J Pharm Biomed Anal"},{"issue":"3","key":"1635_CR50","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1097\/ftd.0000000000000825","volume":"43","author":"Y Mukai","year":"2021","unstructured":"Mukai Y, Yoshida Y, Yoshida T, Kondo T, Inotsume N, Toda T. Simultaneous quantification of BCR-ABL and Bruton tyrosine kinase inhibitors in dried plasma spots and its application to clinical sample analysis. Ther Drug Monit. 2021;43(3):386\u201393. https:\/\/doi.org\/10.1097\/ftd.0000000000000825.","journal-title":"Ther Drug Monit"},{"issue":"11","key":"1635_CR51","doi-asserted-by":"publisher","first-page":"4854","DOI":"10.1111\/bcp.15433","volume":"88","author":"TC Zwart","year":"2022","unstructured":"Zwart TC, Metscher E, van der Boog PJM, Swen JJ, de Fijter JW, Guchelaar HJ, et al. Volumetric microsampling for simultaneous remote immunosuppressant and kidney function monitoring in outpatient kidney transplant recipients. Br J Clin Pharmacol. 2022;88(11):4854\u201369. https:\/\/doi.org\/10.1111\/bcp.15433.","journal-title":"Br J Clin Pharmacol"},{"key":"1635_CR52","doi-asserted-by":"publisher","DOI":"10.1097\/FTD.0000000000000864","author":"L Delahaye","year":"2021","unstructured":"Delahaye L, Veenhof H, Koch BCP, Alffenaar J-WC, Linden R, Stove C. Alternative sampling devices to collect dried blood microsamples: state-of-the-art. Ther Drug Monit. 2021. https:\/\/doi.org\/10.1097\/FTD.0000000000000864.","journal-title":"Ther Drug Monit"},{"key":"1635_CR53","doi-asserted-by":"publisher","DOI":"10.1097\/ftd.0000000000001315","author":"M Meertens","year":"2025","unstructured":"Meertens M, Kerssemakers N, de Vries N, Rosing H, Steeghs N, Beijnen JH, et al. Clinical application of volumetric absorptive microsampling for therapeutic drug monitoring of oral targeted anticancer drugs. Ther Drug Monit. 2025. https:\/\/doi.org\/10.1097\/ftd.0000000000001315.","journal-title":"Ther Drug Monit"},{"key":"1635_CR54","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2023.115820","volume":"168","author":"M Hu","year":"2023","unstructured":"Hu M, Li W, Zhang Y, Liang C, Tan J, Wang Y. Venetoclax in adult acute myeloid leukemia. Biomed Pharmacother. 2023;168:115820. https:\/\/doi.org\/10.1016\/j.biopha.2023.115820.","journal-title":"Biomed Pharmacother"},{"issue":"8","key":"1635_CR55","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1056\/NEJMra2014530","volume":"385","author":"S Hariharan","year":"2021","unstructured":"Hariharan S, Israni AK, Danovitch G. Long-term survival after kidney transplantation. N Engl J Med. 2021;385(8):729\u201343. https:\/\/doi.org\/10.1056\/NEJMra2014530.","journal-title":"N Engl J Med"},{"issue":"2","key":"1635_CR56","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1002\/cncr.33933","volume":"128","author":"HM Kantarjian","year":"2022","unstructured":"Kantarjian HM, Jain N, Garcia-Manero G, Welch MA, Ravandi F, Wierda WG, et al. The cure of leukemia through the optimist\u2019s prism. Cancer. 2022;128(2):240\u201359. https:\/\/doi.org\/10.1002\/cncr.33933.","journal-title":"Cancer"},{"issue":"9","key":"1635_CR57","doi-asserted-by":"publisher","first-page":"617","DOI":"10.6004\/jnccn.2024.0056","volume":"22","author":"LR Baden","year":"2024","unstructured":"Baden LR, Swaminathan S, Almyroudis NG, Angarone M, Baluch A, Barros N, et al. Prevention and treatment of cancer-related infections, Version 3.2024, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2024;22(9):617\u201344. https:\/\/doi.org\/10.6004\/jnccn.2024.0056.","journal-title":"J Natl Compr Canc Netw"}],"container-title":["Clinical Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-026-01635-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40262-026-01635-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-026-01635-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T15:07:21Z","timestamp":1781622441000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40262-026-01635-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,22]]},"references-count":57,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["1635"],"URL":"https:\/\/doi.org\/10.1007\/s40262-026-01635-3","relation":{},"ISSN":["0312-5963","1179-1926"],"issn-type":[{"value":"0312-5963","type":"print"},{"value":"1179-1926","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,22]]},"assertion":[{"value":"12 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Dirk Jan Moes is an editorial board member of\n                      Clinical Pharmacokinetics\n                      . He was not involved in the selection of peer reviewers for the manuscript or any of the subsequent editorial decisions. Jesse Swen has received lecture fees from Lundbeck, paid directly to his employer (Leiden University Medical Center). The other authors declare that they have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All analyses underlying the conclusions are described in the article and its Supplementary Materials. Owing to institutional and ethical restrictions, the datasets generated and\/or analyzed in this study are not publicly available; deidentified datasets and the analysis can be obtained from the corresponding author on reasonable request. Scripts were developed in a Dutch clinical context and contain both Dutch- and English-language elements, reflecting the original data structure.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data availability statement"}},{"value":"This study was approved by the institutional review board of Leiden University Medical Center (approval number: NL86162.058.24). All procedures were conducted in accordance with the ethical standards of the Declaration of Helsinki.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Concept and design: D.J.A.R.M. and A.D.L.; acquisition of data: J.R., A.D.L., A.A., and P.vdB.; formal analysis and visualization: A.D.L. and J.R.; methodology and validation: A.D.L., D.J.A.R.M., E.M., J.R., and J.J.S; Project administration: J.R., A.D.L., and E.M.; supervision: D.J.A.R.M. and J.J.S; writing\u2014original draft: A.D.L; review and editing: A.D.L., D.J.A.R.M., A.A., E.M., J.R., P.vdB, and J.J.S. All authors read and approved the final manuscript.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}